Telemedicine Qualifying Transition Between Tertiary and Primary Health Care in Stable Coronary Artery Disease Patients (Tele_DAC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02489565|
Recruitment Status : Unknown
Verified July 2015 by Hospital de Clinicas de Porto Alegre.
Recruitment status was: Recruiting
First Posted : July 3, 2015
Last Update Posted : July 3, 2015
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Other: Telemedicine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||264 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Telemedicine in Qualifying Care Transition Between Tertiary and Primary Health Care Among Stable Coronary Artery Disease Patients: a Randomized Non-inferiority Trial|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||November 2017|
No Intervention: Tertiary care
Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
Experimental: Primary care
Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
Other Name: Primary care with the support of telemedicine
- Number of participants that stay in Canadian Cardiovascular Society (CCS) Functional Classification of Angina I and II as a measure of safety [ Time Frame: within one year after discharge ]Not evolve into a higher class than the measure before the intervention
- Number of participants with instability of the disease [ Time Frame: within one year after discharge ]the need to seek emergency care for cardiovascular disease post intervention.
- blood pressure control [ Time Frame: within one year after discharge ]verified to maintain systemic blood pressure from the observation of a variation of at least 5% in pre and post intervention measurements
- dyslipidemia control [ Time Frame: within one year after discharge ]verified to maintain dyslipidemia control through laboratory examination, from the observation of a variation of at least 5% in pre and post intervention measurements of Low Density Lipoproteins (LDL) in blood
- diabetes control [ Time Frame: within one year after discharge ]verified to maintain diabetes control through laboratory examination, from the observation of a variation of at least 5% in pre and post intervention measurements of fasting glucose in the blood
- Number of participants with control of tobacco [ Time Frame: within one year after discharge ]remain without smoking for non smokers; and smoking cessation for smokers
- Number of participants in physical activity [ Time Frame: within one year after discharge ]maintenance or start regular physical activity post intervention
- Access to primary health care [ Time Frame: within six months and one year after discharge ]medical consultation in Basic Health Unit held with assessment of current medications and providing prescription.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02489565
|Contact: Carisi A Polanczyk, PhD||+55 51 email@example.com|
|Contact: Joanna Lyra, PhD||+ 55 51 firstname.lastname@example.org|
|Instituto de Avaliação de Tecnologia em Saúde (Institute of Technology Assessment in Health)||Recruiting|
|Porto Alegre, Rio Grande do Sul, Brazil, 90035-903|
|Contact: Carisi A Polanczyk, PhD +555133596359 email@example.com|
|Contact: Joanna L Batista, PhD +555133596325 firstname.lastname@example.org|
|Sub-Investigator: Mariana V Furtado, PhD|
|Sub-Investigator: Natan Katz, MsC|
|Principal Investigator:||Carisi A Polanczyk, PhD||Hospital de Clínicas de Porto Alegre|